Results 161 to 170 of about 60,915 (280)

A Framework for Emergency Department–Integrated Hepatitis C Test‐and‐Treat in the United States

Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Despite the availability of curative, direct‐acting antiviral therapy, hepatitis C virus elimination remains incomplete. Losses across the care cascade continue to limit impact, from initial diagnosis to sustained virologic response. Fewer than 1/3 of individuals ultimately achieve cure. These gaps reflect a delivery system that does not align
Saeed S. Graham
wiley   +1 more source

Sustained HBsAg clearance induced by pegylated interferon α-2b in HBeAg-negative patients with low baseline HBsAg. [PDF]

Front Cell Infect Microbiol
Wen C, He T, Zha G, Li A, Wang Z, Zhou Z, Cai D, Zhang D, Peng M, Shi X, Ren H.   +10 more
europepmc   +1 more source

HBsAg loss in chronic hepatitis B patients with an HBsAg decline plateau can be enhanced by intermittent PEG-IFN treatment. [PDF]

Front Cell Infect Microbiol
Cao W, Xie S, Hao H, Deng W, Zhang L, Lu Y, Liu R, Wang S, Li X, Zhang Z, Wei X, Gao Z, Yao L, Wang S, Gao Y, Wang Y, Xu M, Hu L, Xie Y, Li M.   +19 more
europepmc   +1 more source

[Excretion of HBsAg in the HBsAg carrier].

Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1977
S, Kashiwagi, M, Kaji, K, Shibata, Y, Kimura, Y, Swae   +4 more
openaire   +1 more source

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, Christine John, Ralph Link, Hartwig Klinker, Uta Merle, Markus Cornberg, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer   +10 more
wiley   +1 more source

Impact of hepatitis B virus surface antigen mutations in the major hydrophilic region on antigen detectability. [PDF]

Front Cell Infect Microbiol
He C, Gu X, Liu Y, Shen H, Xiang Z, Xu Z.   +5 more
europepmc   +1 more source

Emergency Department Opt‐Out Testing for Hepatitis B: A Two‐Year UK Multicentre Evaluation of Outcomes Across Seven Sites

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background and Aims An estimated 270 000 people in the UK live with hepatitis B infection, the leading global cause of liver cancer. In 2022, opt‐out hepatitis B testing was introduced in emergency departments (ED) in London. We conducted a 2‐year multicentre evaluation of this programme across seven sites.
Jennifer J. Plunkett, Basil Ahmad, Amy Teague, Tanzina Haque, Stephanie Paget, Jennifer Hart, Maximillian Habibi, Jonathan Durban, Shiny Jaimes, Sally Thomas, Helen Boothman, Supa Chantschool, Philippa C. Matthews, Rachel Hill‐Tout, Daniel Forton, Douglas Macdonald   +15 more
wiley   +1 more source

Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease. [PDF]

Front Immunol
Zhu C, Yang J, Sheng Y, Fang M.
europepmc   +1 more source

Real‐World Outcomes of Opti‐Hep‐D: An Innovative, Multicentre and Multidisciplinary Program Improving Hepatitis D Cascade of Care

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background and Aim Hepatitis D virus (HDV) infection remains underdiagnosed, and real‐world data on screening and linkage to care are limited. We assessed the implementation of Opti‐Hep‐D, a publicly funded initiative for HDV management in the Spanish region of Catalonia.
Adriana Palom, Ariadna Rando‐Segura, Laura Calatayud‐Samper, Gema Fernández‐Rivas, Alicia Sellés‐Sanchez, Saray Mormeneo‐Bayo, Dúnia Pérez del Campo, Eva del Corral, Tomàs Balari, Rosa Maria Morillas, Adrià Rodríguez‐Castellano, Patricia Huelin, Carmen Lopez, Darly Salazar, Joana Villaverde, Indiana Abdo, José Castellote, Joan Carles Quer Boniquet, Carles Aracil Blanch, Andrés Marco, Maria Buti   +20 more
wiley   +1 more source

Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy. [PDF]

Hepatol Commun
Shigeno S, Kodama T, Murai K, Sometani E, Yasuda K, Tahata Y, Nishio A, Tanaka S, Miyazaki M, Ohkawa K, Kakita N, Tawara S, Yakushijin T, Hikita H, Toyoda H, Takehara T.   +15 more
europepmc   +1 more source